Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

ABSTRACT:

Background

Pembrolizumab combined with neoadjuvant chemotherapy is the standard of care for stage II-III triple-negative breast cancer (TNBC) based on the KEYNOTE-522 trial. However, 13 % of patients experienced immune-related adverse events (irAEs) of grade ≥3 in the trial. This study aims to describe patterns of irAEs in a real-world scenario during treatment with pembrolizumab for early-stage TNBC.

Methods

Patients treated with neoadjuvant pembrolizumab plus chemotherapy across ten Brazilian cancer centers were evaluated in the Neo-Real/GBECAM0123 study. This analysis focuses on irAE evaluation, including time to onset, management, and association between irAEs and pathological complete response (pCR).

Results

A total of 368 patients were included. Overall, 31 % of

SUBMITTER: Andrade MO 

PROVIDER: S-EPMC12496205 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature